PDE5 inhibitors: in vitro and in vivo pharmacological profile.

  title={PDE5 inhibitors: in vitro and in vivo pharmacological profile.},
  author={Dimitrios Kouvelas and Antonis Goulas and Georgios Papazisis and Chrysa Sardeli and Chryssa Pourzitaki},
  journal={Current pharmaceutical design},
  volume={15 30},
PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors--sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis)--are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena), is currently marketed. In the present review the… CONTINUE READING
17 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…